oppn parties Covid Vaccines Cannot Be Priced As Any Other Vaccine

News Snippets

  • After both candidates got 34 votes in HP. Congress' Abhishek Singhvi lost in the draw of lots as the BJP candidate was declared winner
  • ED issues 8th summons to Delhi CM Arvind Kejriwal in the excise policy scam case
  • Prime Minister Modi introduced the three IAF group captains - Prashanth Nai, Ajit Kirshnan and Angad Pratap - and Wing Commander Shubhangshu Shukla, who have been shortlisted for the first manned space mission of ISRO
  • Centre appointed former SC judge A M Khanwilkar as the new Lokpal. It also named three judicial and three non-judicial members of the Lokpal panel
  • A 9-judge Supreme Court bench started hearings on whether states are entitled to tax mineral-rich land in their respective states
  • Taking note of the huge disparity in charges in government and private hospitals for most treatment procedures, the Supreme Court asked the Centre to strictly enforce the CGHS rates or warned that the court would have to step in
  • Calcutta HC ruled that regardless of a woman employee being regualr or on contract and whether her contract permitted maternity leave, employers cannot deny childbirth and maternity leave to any women employee as it 'seeks to create a class within a class which is not permissible'
  • Sebi asks MF companies to disclose more risks associated with their small and mid cap funds
  • Vodafone Idea board approves Rs 45000cr funding infusion
  • NCLT clears Hinduja acquisition of Reliance Capital at Rs 9650cr upfront payment within 90 days of approval of resolution plan
  • Stocks returned to winning ways on Tuesday: Sensex gained 305 points to 73095 and Nifty 76 points to 22198
  • Commonwealth Chess championships: Mitrabha Guha wins title by scoring 7.5 points in 9 rounds
  • WPL: RCB beat Gujarat Giants by 8 wickets
  • Bengal starts paying MNREGA workers out of own funds as Central disbursement is stopped due to alleged 'discrepancies' in accounts
  • ISC chemistry paper postponed to March 21 just hours before start of exam due to "unforeseen circumstances"
Cross-voting in Rajya Sabha elections enables BJP to snatch seats in UP & Himachal /////// Congress government in Himachal in trouble as some MLAs revolt
oppn parties
Covid Vaccines Cannot Be Priced As Any Other Vaccine

By Sunil Garodia
First publised on 2021-06-16 11:38:25

About the Author

Sunil Garodia Editor-in-Chief of indiacommentary.com. Current Affairs analyst and political commentator.

Both Serum Institute and Bharat Biotech, makers of Covishield and Covaxin respectively, have urged the government to raise the price at which it is acquiring the Covid vaccines from them. Their argument is that the average price (reported to be in the range of Rs 200 to Rs 250 per dose excluding taxes) now is not sustainable due to the fact that a lot of costly R&D went into developing the vaccines and they have to upgrade their facilities. They say that at current price, they are just recouping their costs and making a small profit. But, they say, they have to make super profits to recoup R&D costs and for future R&D.

Their arguments are perfectly logical. But that is in the case of any other vaccine. In case of Covid vaccines, these arguments do not hold. For, most other vaccines take years to develop and then several more years to test and market. The Covid vaccines were developed, tested and administered in a record 10 to 11 months. Then, most other vaccines are sold in thousands of doses over a period of several years. Here we are talking about millions of doses in a span of just one year. Also, most other vaccines need extensive marketing which is a costly exercise. Commissions have to be paid at each point in the sales channel. Even doctors have to be 'paid' to prescribe their brand if there are competing vaccines. Companies also have attractive schemes for the trade (like "buy three, get two free" etc) for most other vaccines. Lastly, in all other vaccines, there are expired and unsold products, sometimes to the extent of 5% of sales, which the companies have to take back from the market. The companies are saving all these costs. Further, in the case of Covaxin, the government of India, through ICMR, has contributed funds in R&D.

If the companies say that these costs are not sustainable, the government must sit with them to renegotiate the price. But the pricing of vaccines which are to be procured in millions of doses in a short span of time and for which the government is making advance payment in part cannot be priced in a manner similar to any other vaccine. The companies have to keep this in mind.